This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

This study has been completed.
Information provided by:
Saitama Medical University Identifier:
First received: September 13, 2007
Last updated: September 14, 2007
Last verified: September 2007
Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Condition Intervention
Cardiovascular Disease Drug: candesartan or valsartan or losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Saitama Medical University:


Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 30 to 80 years of age
  • Receiving hemodialysis at least 12 months and less than 5 years
  • Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria:

  • Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530595

Sponsors and Collaborators
Saitama Medical University
Study Director: Hiromichi Suzuki, MD, PhD Department of Nephrology, Saitama Medical University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00530595     History of Changes
Other Study ID Numbers: S-01
Study First Received: September 13, 2007
Last Updated: September 14, 2007

Keywords provided by Saitama Medical University:

Additional relevant MeSH terms:
Cardiovascular Diseases
Angiotensin Receptor Antagonists
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents processed this record on August 22, 2017